Stem Cell Therapy for Alzheimer's Disease
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
Advanced MSC treatments targeting neuroinflammation, promoting neurogenesis, and protecting surviving neurons to slow cognitive decline.
Can stem cell therapy help Alzheimer's disease?
Mesenchymal stem cell therapy is not an approved treatment for Alzheimer's disease. A small number of early-phase trials have reported acceptable safety, but none have shown a consistent, clinically meaningful improvement in cognition or function. Approved therapies — cholinesterase inhibitors, memantine, and, in selected patients, anti-amyloid antibodies — plus caregiver support remain the interventions with evidence and should continue.
Key facts
- Approval status
- Not approved for Alzheimer's disease
- Trial findings
- Small samples, cognition benefit not demonstrated
- Standard care
- Cholinesterase inhibitors, memantine, anti-amyloid where eligible
What we know
- Phase 1/2 MSC studies in mild-to-moderate Alzheimer's have reported short-term safety.
What remains uncertain
- Whether MSC administration produces a measurable change on validated cognitive scales versus placebo.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Alzheimer's disease
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — early-stage only
- Randomised trials?
- Small randomised and open-label phase 1/2 trials; no efficacy signal established
- Main outcomes studied
- Cognitive scales (ADAS-Cog, MMSE)
- Biomarkers
- Imaging
- Safety
- Long-term evidence
- Very limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Alzheimer's disease — PubMed
- Randomised controlled trials — Alzheimer's disease — PubMed
- Registered MSC trials — Alzheimer's disease — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
What is Alzheimer's Disease?
Alzheimer's disease is the most common form of dementia, affecting over 55 million people worldwide. It is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta plaques and tau protein tangles in the brain, leading to neuronal death and cognitive decline.
Traditional treatments offer limited symptom management without addressing the underlying neurodegeneration. Mesenchymal stem cell (MSC) therapy represents a promising approach by targeting the root causes of neuronal loss, reducing neuroinflammation, and promoting the brain's natural repair mechanisms.
At StemCell Longevita, we use umbilical cord-derived Wharton's jelly MSCs delivered via intrathecal and intravenous routes to maximize therapeutic benefit for Alzheimer's patients, with treatment protocols developed in collaboration with leading neurology experts.
How Stem Cell Therapy Helps Alzheimer's Disease
Neuroinflammation Reduction
MSCs suppress activated microglia and reduce pro-inflammatory cytokine production in the brain, slowing the neuroinflammatory cascade that drives neuronal death.
Neurogenesis Promotion
Stem cells release neurotrophic factors (BDNF, NGF, GDNF) that stimulate the growth of new neural connections and support surviving neuron health.
Neuroprotection
MSC-derived exosomes protect existing neurons from oxidative stress and apoptosis, preserving cognitive function and slowing disease progression.
Cognitive Function Support
Many patients experience improvements in memory recall, attention span, language abilities, and daily living activities following MSC therapy.
Treatment Process
Your step-by-step treatment journey at StemCell Longevita
Neurological Assessment
Comprehensive cognitive testing, brain MRI, and biomarker analysis to evaluate disease stage and create a personalized protocol.
Treatment Planning
Custom protocol design based on cognitive assessment results, disease duration, and individual patient characteristics.
MSC Preparation
High-quality Wharton's jelly mesenchymal stem cells prepared in our GMP-certified laboratory with 97% viability guarantee.
Dual-Route Administration
Combined intrathecal (spinal) and intravenous delivery for maximum brain bioavailability and systemic anti-inflammatory effects.
Monitoring & Follow-Up
Post-treatment cognitive assessments at 3, 6, and 12 months to track improvements and plan maintenance protocols.
Patient Experiences
Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul
"After 8 years of decline, I finally feel like I'm moving forward again. The team in Istanbul gave me something my neurologist at home couldn't — hope backed by real results."
"Within three months of treatment, our daughter started calling us by name. Her teachers noticed the difference before we even told them about the therapy."
Understanding the regenerative approach for Alzheimer's disease
Alzheimer's disease needs comprehensive neurologist-led management. A consultation reviews diagnosis, stage, current medication, support needs, and travel safety before discussing whether an additional regenerative approach can be considered.
This page is for information and does not replace advice from your usual specialist. Eligibility, delivery route, and follow-up are determined only after an individual medical review.
Who may be considered?
Suitability depends on diagnosis, disease stage, general health, support needs, and whether international travel can be undertaken safely:
- Patients with a specialist-confirmed diagnosis and current neurological records
- People whose stage, general health, and medication can be reviewed before travel
- Patients with a family member or caregiver involved in planning and follow-up
- Those seeking an evidence-limited adjunct while continuing established dementia care
How the clinical pathway is planned
The recommended plan is individualised after records are reviewed; it is not a fixed, one-size-fits-all treatment package.
- 1
Remote medical-record review
The team reviews diagnosis, history, imaging or test results, current medication, and the goals you want to discuss.
- 2
Clinical suitability assessment
A clinician considers whether a regenerative approach can be discussed safely, including the delivery route and the need for any further testing.
- 3
Written plan before travel
If appropriate, you receive a written outline of the proposed approach, expected visit schedule, exclusions, and coordination arrangements.
- 4
In-person confirmation and follow-up
The plan is reconfirmed after an in-person assessment in Istanbul, with remote follow-up arranged after the visit.
What the approach is intended to address
Potential regenerative mechanisms for neurodegeneration remain under study. They do not remove the need for established dementia care, and expected outcomes must be discussed cautiously.
Evidence and outcomes vary by diagnosis, disease stage, delivery approach, and the individual. The consultation is the place to discuss what is known, what remains uncertain, and whether an approach is appropriate for you.
Expected timeline and follow-up
Alzheimer's benefits develop gradually after treatment, with early-stage patients typically showing the strongest response:
- 1
Treatment
Combined IV and intrathecal MSC delivery maximizes brain exposure via the cerebrospinal fluid during a 3-5 day stay in Istanbul.
- 2
Cognitive stabilization (3-6 months)
Patients may experience stabilization or improvement in memory recall, attention and focus, verbal communication, spatial awareness, and daily-activity ability, with benefits developing over 3-6 months.
- 3
Ongoing follow-up
Progress is tracked through a 12-month cognitive follow-up program.
When treatment may not be appropriate
While MSC therapy is safe for most patients, certain conditions may be contraindications. Treatment is not suitable in the following situations:
- Active cancer or ongoing chemotherapy/radiation treatment
- Active systemic infections requiring IV antibiotics
- Severe organ failure (end-stage kidney, liver, or heart failure)
- Pregnancy or planned pregnancy within 3 months
- Known allergy to any component used in cell processing
Our medical team conducts a thorough screening process to identify any contraindications before treatment. If stem cell therapy is not appropriate for your situation, we will advise you honestly.
Questions to discuss before deciding
Travel and care-coordination path
Treatment at StemCell Longevita is an all-inclusive medical-travel program from your first consultation to your 12-month follow-up:
- 1
Free online consultation & medical record review
Your journey begins with a free remote consultation. Our medical team reviews your medical records, imaging, and history to assess suitability — no travel required at this stage.
- 2
Written personalized protocol & treatment plan
You receive a written, personalized treatment protocol and plan detailing the recommended cell dosing, delivery route, and expected schedule for your condition.
- 3
Travel booking with clinic assistance
Our team assists with your travel arrangements. Every package includes VIP airport transfer and a 5-star hotel stay with breakfast included for you and an accompanying family member.
- 4
On-arrival medical evaluation in Istanbul
On arrival you undergo an in-person medical evaluation at the JCI-accredited Liv Hospital Ulus in Istanbul before treatment begins.
- 5
Treatment days
Treatment is administered over your stay, with a typical total stay of 3-5 days including evaluation, treatment, and monitoring.
- 6
Return home & 12-month telemedicine follow-up
After returning home you receive a 12-month telemedicine follow-up program with regular remote check-ins to track your progress.
All Regenerative Medicine Applications
Explore our comprehensive range of regenerative medicine applications for various conditions. Click any option to learn more.
Related Articles
Explore our in-depth research articles and guides on related treatments and therapies.
Cerebral Palsy & Regenerative Medicine: New Hope for Children
Discover how mesenchymal stem cell approaches are supporting the care landscape for cerebral palsy, offering potential motor function improvement and quality of life for children and families worldwide.
Read ArticleRegenerative Medicine Application for Autism Spectrum Disorder
Explore the promising potential of regenerative medicine in addressing autism spectrum disorder symptoms, including potential improvements in communication, social interaction, and behavioral patterns.
Read ArticleStroke Progress: How Stem Cells Support Neurological Wellness
Exploring the potential of regenerative medicine in stroke rehabilitation, including mechanisms of action and reported improvements in motor and cognitive function.
Read ArticleRelated clinical questions
Where this page sits in the wider picture.